The Technical Analyst
Liquidia Technologies Inc [LQDA]
Exchange: NasdaqCM Sector: Healthcare Industry: Biotechnology
Liquidia Technologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.68% $5.37
Last updated: 8 aug 2022 - 0:22
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 345.53 mill |
| EPS: | -0.800 |
| P/E: | 0.000 |
| Earnings Date: | Nov 04, 2021 |
| SharesOutstanding: | 64.34 mill |
| Avg Daily Volume: | 1.624 mill |
| RATING 2022-08-05 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.53 (21.55%) $1.157 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.94 - 5.80 ( +/- 7.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-07-28 | Lippe Robert A | Buy | 25 000 | Stock Option (Right to Buy) |
| 2022-07-28 | Schundler Russell | Buy | 150 000 | Stock Option (Right to Buy) |
| 2022-07-28 | Kaseta Michael | Buy | 150 000 | Stock Option (Right to Buy) |
| 2022-07-28 | Moomaw Scott | Buy | 75 000 | Stock Option (Right to Buy) |
| 2022-07-18 | Saggar Rajeev | Buy | 200 000 | Non-Qualified Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 34.54 |
| Last 100 transactions |
| Buy: 17 110 773 | Sell: 11 889 386 |
Forecast:
16:00 - $5.37
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.37
Forecast 2: 16:00 - $5.37
Forecast 3: 16:00 - $5.37
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.37 (2.68% ) |
| Volume | 0.985 mill |
| Avg. Vol. | 1.624 mill |
| % of Avg. Vol | 60.63 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LQDA
158 Signals | Accuracy: 13.29% | Accuracy Buy: 13.92% | Accuracy Sell: 12.66%
Avg return buy: -0.02 % | Avg return sell: 0.09 %
$1 invested is now $0.98 or -1.90% since 25-07-22
| Date | Signal | @ | Closed | % | Aug 5 - 14:27 | sell | $5.39 | N/A | Active |
|---|---|---|---|---|
| Aug 5 - 13:46 | buy | $5.40 | $5.39 @ Aug 5 - 14:27 | -0.09% |
| Aug 5 - 13:28 | sell | $5.39 | $5.40 @ Aug 5 - 13:46 | 0.09% |
| Aug 5 - 12:10 | buy | $5.36 | $5.39 @ Aug 5 - 13:28 | 0.56% |
| Aug 5 - 12:09 | sell | $5.36 | $5.36 @ Aug 5 - 12:10 | 0.00% |
| Aug 5 - 12:06 | buy | $5.36 | $5.36 @ Aug 5 - 12:09 | 0.00% |
| Aug 5 - 11:01 | sell | $5.34 | $5.36 @ Aug 5 - 12:06 | 0.47% |
| Aug 5 - 10:12 | buy | $5.37 | $5.34 @ Aug 5 - 11:01 | -0.62% |
| Aug 4 - 14:32 | sell | $5.30 | $5.37 @ Aug 5 - 10:12 | 1.29% |
| Aug 4 - 14:19 | buy | $5.32 | $5.30 @ Aug 4 - 14:32 | -0.28% |
LQDA
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. The company is headquartered in Durham, North Carolina and currently employs 63 full-time employees. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
Latest Press Releases
2022-07-25 08:51:00 - Press Release
Liquidia Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Morrisville, n.c., july 25, 2022 (globe newswire) -- liquidia corporation (nasdaq: lqda) today announced the grant of an inducement stock option exercisable for 2,000 shares of liquidia's common stock to a newly hired non-executive employee under the liquidia corporation 2022 inducement plan (the “inducement plan”). the stock option was granted as an inducement material to the grantee's acceptance of employment with liquidia (or one of its subsidiaries) as a component of the grantee's employment compensation in accordance with nasdaq listing rule 5635(c)(4).
2022-07-21 16:30:00 - Press Release
Liquidia Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Morrisville, n.c., july 21, 2022 (globe newswire) -- liquidia corporation (nasdaq: lqda) today announced that, in connection with the previously announced appointment of rajeev saggar, m.d., liquidia's new chief medical officer, it has agreed to grant him an employment inducement equity award. as previously disclosed in a current report on form 8-k filed with the securities and exchange commission on june 22, 2022 (“form 8-k”), liquidia has agreed to grant dr. saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of liquidia's common stock under the liquidia corporation 2022 inducement plan (the “inducement plan”)...
2022-07-19 16:30:00 - Press Release
Liquidia Receives Favorable Ruling In Inter Partes Review against United Therapeutics Patent
Morrisville, n.c., july 19, 2022 (globe newswire) -- liquidia corporation (nasdaq: lqda) announced today that the u.s. patent trial and appeal board (ptab) ruled in its favor in the inter partes review (ipr) proceeding against u.s. patent no. 10,716,793 (‘793 patent) owned by united therapeutics corporation (utc) and listed in the orange book for tyvaso® (treprostinil inhalation solution). in its ruling, the ptab found that, based on the preponderance of the evidence, all the claims of the '793 patent have been shown to be unpatentable.
2022-06-27 06:26:00 - Press Release
Liquidia Corporation Added To Russell 2000® And 3000® Indexes
Morrisville, n.c., june 27, 2022 (globe newswire) -- liquidia corporation (nasdaq: lqda) announced today that the company was added as a member of the us small-cap russell 2000® index, effective after the us market opens on june 27, as part of the 2022 russell indexes reconstitution. membership in the russell 2000® index, which remains in place for one year, is based on membership in the broad-market russell 3000® index. the stock also was automatically added to the appropriate growth and value indexes.
2022-06-24 16:15:00 - Press Release
Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Morrisville, n.c., june 24, 2022 (globe newswire) -- liquidia corporation (nasdaq: lqda) today announced the grant of inducement stock options exercisable for an aggregate of 24,800 shares of liquidia's common stock to newly hired non-executive employees under the liquidia corporation 2022 inducement plan (the “inducement plan”). each stock option was granted as an inducement material to the grantee's acceptance of employment with liquidia (or one of its subsidiaries) as a component of the grantee's employment compensation in accordance with nasdaq listing rule 5635(c)(4).
Latest News
2022-08-04 08:18:00 - GlobeNewsWire
Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022
MORRISVILLE, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
2022-08-01 06:24:00 - GlobeNewsWire
Liquidia to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next week:
2022-06-03 07:00:00 - PennyStocks
What to Know About Buying Penny Stocks on June 3rd
Here's what you need to know about trading penny stocks on June 3rd The post What to Know About Buying Penny Stocks on June 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-26 16:34:00 - The Motley Fool
Why Liquidia Stock Rose as Much as 22% Higher Today
A major bank initiated coverage of the stock with a very bullish recommendation and price target.
2022-05-12 13:49:04 - Seeking Alpha
Liquidia Corporation (LQDA) CEO Roger Jeffson Q12022 Results - Earnings Call Transcript
Liquidia Corporation(NASDAQ:LQDA ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Jason Adair - SVP, Corporate Development and Strategy Roger Jeffs - CEO Mike Kaseta - CFO Rusty Schundler - General Counsel Conference Call Participants Serge Belanger - Needham & Company Julian Harrison - BTIG Andreas Argyrides - Wedbush Operator Good morning, and welcome, everyone, the Liquidia Corporation First Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Howard, and I will be your conference operator today.
2022-05-12 09:47:34 - Zacks Investment Research
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -50% and 7.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-27 06:31:55 - InvestorPlace
7 Stocks to Watch for Major Insider Trading Clues
These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared first on InvestorPlace.
2022-03-17 11:18:02 - Seeking Alpha
Liquidia Corporation's (LQDA) CEO Roger Jeffs on Q4 2021 Results - Earnings Call Transcript
Liquidia Corporation's (LQDA) CEO Roger Jeffs on Q4 2021 Results - Earnings Call Transcript
2022-03-17 09:02:04 - Zacks Investment Research
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -109.09% and 11.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-03-10 11:17:48 - Zacks Investment Research
Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.